Write in a clean editor, then format for Cardio-Oncology in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Cardio-Oncology is a peer-reviewed journal published by BMC (BioMed Central), covering Chemotherapy-induced cardiotoxicity and mitigation, Lung Cancer Research Studies, Cancer Treatment and Pharmacology. Over its lifetime it has published 565 papers, which have received 4,238 citations.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Cardio-Oncology. 2023;12(3):45–58.
Formats any DOI in Cardio-Oncology style. No sign-up. |
| Publishes research in | Chemotherapy-induced cardiotoxicity and mitigation Lung Cancer Research Studies Cancer Treatment and Pharmacology Cardiac Imaging and Diagnostics Cardiovascular Function and Risk Factors |
| ISSN | 2057-3804 |
| Citation impact (2-yr) | 2.08 |
| h-index | 32 |
| i10-index | 124 |
| Article processing charge | $2,072 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | University of Pennsylvania |
| Journal website | link.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can cause short- and long-term cardiotoxicity. The clinical implications of this cardiotoxicity become more important with the increasing use of cardiotoxic drugs. The implications are especially serious among…
BACKGROUND: 5-Fluorouracil (5-FU) is an antimetabolite chemotherapy used for a variety of solid tumors. It has the potential to cause a wide spectrum of cardiotoxicity, ranging from asymptomatic electrocardiographic changes to cardiomyopathy and subsequent cardiac failure. Main body of the abstract: We present two descriptive cases of new-onset severe cardiomyopathy induced by 5-FU followed by…
The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication makes difficult to design successful preventive or curative measures. Although cardiomyocyte has been considered a classical cellular target, other cells including various types of undifferentiated cells are…
Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of anthracyclines, but in the USA and some European countries, its use had been restricted to adults with advanced breast cancer receiving a cumulative doxorubicin (an anthracycline) dose > 300 mg/m2. We…
BACKGROUND: Cancer is a chronic condition that induces significant emotional and physical stress, which may increase the risk for developing Takotsubo cardiomyopathy (TCM). MAIN BODY: Takotsubo cardiomyopathy, also known as stress cardiomyopathy, is a clinical syndrome that generally presents as chest pain mimicking acute coronary syndrome or as an acute heart failure characterized by severe…
